Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
作者信息
Nowakowski Grzegorz S, Yoon Dok Hyun, Mondello Patrizia, Joffe Erel, Peters Anthea, Fleury Isabelle, Greil Richard, Ku Matthew, Marks Reinhard, Kim Kibum, Zinzani Pier Luigi, Trotman Judith, Sabatelli Lorenzo, Waltl Eva E, Winderlich Mark, Sporchia Andrea, Kurukulasuriya Nuwan C, Cordoba Raul, Hess Georg, Salles Gilles
机构信息
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Department of Oncology, Asan Medical Center, Songpa‑gu, Seoul, South Korea.
出版信息
Ann Hematol. 2023 Sep;102(9):2643-2644. doi: 10.1007/s00277-023-05321-3.
Abstract
摘要
相似文献
1
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Ann Hematol. 2023 Sep;102(9):2643-2644. doi: 10.1007/s00277-023-05321-3.
2
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12.
3
Economic evaluation of polatuzumab-bendamustine-rituximab tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL.
J Med Econ. 2021 Nov;24(sup1):14-24. doi: 10.1080/13696998.2021.2007704.
4
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Lancet Haematol. 2021 Dec;8(12):e891-e901. doi: 10.1016/S2352-3026(21)00311-2.
5
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648.
6
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Drugs Today (Barc). 2020 Apr;56(4):287-294. doi: 10.1358/dot.2020.56.4.3127026.
7
Polatuzumab Vedotin: First Global Approval.
Drugs. 2019 Sep;79(13):1467-1475. doi: 10.1007/s40265-019-01175-0.
8
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.
9
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.
Hemasphere. 2022 Nov 11;6(12):e798. doi: 10.1097/HS9.0000000000000798. eCollection 2022 Dec.
10
Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options.
J Clin Med. 2023 Dec 22;13(1):70. doi: 10.3390/jcm13010070.
引用本文的文献
1
Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2309701. doi: 10.1080/21645515.2024.2309701. Epub 2024 Feb 1.
Zotero 插件